Frequency Electronics, Inc. — Form 10-Q Summary
Business context and period: The filing covers the fiscal third quarter and first nine months ended January 31, 2024 (fiscal year ends April 30). The company makes precision time-and-frequency control products and related systems for satellite, U.S. government/defense, telecommunications, and other commercial markets. Its reportable segments are FEI-NY and FEI-Zyfer. Amounts below are in U.S. dollars; financial statement figures are in millions unless noted.
Financial performance and position
| Metric | Three months ended Jan. 31 | Nine months ended Jan. 31 |
|---|---|---|
| Revenue | $13.714m vs. $10.620m (+29.1%) | $39.698m vs. $27.773m (+42.9%) |
| Gross profit / margin | $3.104m / 22.6%, vs. $3.465m / 32.6% | $12.302m / 31.0%, vs. $3.810m / 13.7% |
| Operating income (loss) | $(0.473)m vs. $0.325m | $2.525m vs. $(5.065)m |
| Net income (loss) | $0.130m vs. $(0.316)m; EPS $0.01 vs. $(0.03) | $2.969m vs. $(5.747)m; EPS $0.32 vs. $(0.62) |
| Operating cash flow | $1.226m vs. $1.948m for the comparable nine-month period |
- Quarterly revenue growth came from both segments. FEI-NY revenue rose 37.9% to $11.610m; FEI-Zyfer rose 37.2% to $3.403m, before intersegment eliminations. For the nine months, FEI-NY grew 32.3% and FEI-Zyfer 98.0%.
- Revenue growth reflected prior-period contract awards moving into production. For the nine months, government non-space revenue was 53% of total (47% prior year); satellite revenue was 41% (46% prior year).
- Quarterly gross margin fell due to unexpected costs on fixed-price and customer-funded new-product development, including a design issue. Nine-month margin improved as earlier technical challenges were resolved, programs ran more efficiently, and cost reductions contributed.
- Cash and cash equivalents were $11.663m at January 31, 2024; an additional $0.941m was restricted for a contract letter of credit. Working capital was approximately $24.1m and the current ratio was 1.9:1.
- Cash from operations was $1.2m; investing used $0.7m, principally capital expenditures. There were no financing cash flows in the period. Prior-year investing cash flow included $11.0m of marketable-security redemptions, and prior-year financing included a $9.4m dividend.
- Total liabilities were $41.071m, including $6.499m of operating lease liabilities and $8.190m of deferred compensation. The company had no credit-facility borrowings and no borrowing capacity as of January 31, 2024.
Changes, outlook, and risks
- The $0.636m quarterly investment income (and $0.549m for nine months) included proceeds from a life-insurance plan; this helped lift quarterly pretax income despite an operating loss. The filing does not indicate that this source is recurring.
- Contract loss charges were approximately $0.6m for the quarter and $2.1m for nine months, recorded in cost of revenues. Results depend in part on estimates of contract costs to complete and inventory realizability.
- Funded backlog/unsatisfied performance obligations were approximately $67m, up from $57m at April 30, 2023; about 74% was expected to be realized within twelve months. Backlog excludes awards without authorization to proceed and is not a guarantee of future revenue or profit.
- Management gave no specific revenue or earnings guidance. It expects internally generated cash to fund planned R&D and believes liquidity is adequate for short-term needs through at least March 18, 2025 and for foreseeable longer-term needs. Acquisitions remain a possibility and could involve external funding.
- Key risks include dependence on government and other significant customers, competition and technological change, third-party suppliers, raw-material and manufacturing costs, and uncertainty in contract estimates. The company reported no material risk-factor changes from its latest Form 10-K.
- The company’s 4.6% investment in Russian supplier Morion was previously impaired in full; its future status and related transactions remain uncertain because of Russia-related sanctions. The company reported limited purchases from Morion during the period.
Important facts for investors to verify
- Whether new-product development design issues and related fixed-price contract costs are contained, and how contract-loss provisions and estimated completion costs evolve.
- Whether the $67m funded backlog converts to revenue as expected, including the timing and funding status of awards.
- Whether operating cash generation improves, given inventory growth and cash use for investment; distinguish unrestricted cash from restricted cash.
- How much reported earnings benefited from life-insurance proceeds and whether similar non-operating income recurs.
- Exposure to government customers, supplier constraints and sanctions affecting Morion, and any changes to liquidity or financing plans.